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 Supporting information for this article is given via a link at the end of the document 
 
Abstract: Lapatinib (LAP) is an anticancer drug, which is metabolized 
to the N- and O-dealkylated products (N-LAP and O-LAP, 
respectively). In view of the photosensitizing potential of related drugs, 
a complete experimental and theoretical study has been performed 
on LAP, N-LAP and O-LAP, both in solution and upon complexation 
with human serum albumin (HSA). In organic solvent, coplanar locally 
excited (LE) emissive states are generated; they rapidly evolve 
towards twisted intramolecular charge-transfer (ICT) states. By 
contrast, within HSA only LE states are detected. Accordingly, 
femtosecond transient absorption reveals a very fast switching (ca. 2 
ps) from LE (max = 550 nm) to ICT states (max = 480 nm) in solution, 
whereas within HSA the LE species become stabilized and live much 
longer (up to the ns scale). Interestingly, molecular dynamics 
simulation studies confirm that the coplanar orientation is preferred for 
LAP (or to a lesser extent N-LAP) within HSA, explaining the 
experimental results. 
Introduction 
According to the World Health Organization, breast cancer has 
become in 2018 the second leading cause of death worldwide.[1] 
The epidermal growth factor receptor (EGFR) is a 
transmembrane protein belonging to the same family as tyrosine 
kinase receptors HER2, HER3, and HER4, which controls a 
variety of cell functions including cell differentiation, proliferation, 
apoptosis, migration and angiogenesis.[2] Pathological alterations 
of EGFR and HER2, including kinase-activating mutation or 
overexpression, may result in the appearance of different types of 
cancer, such as pancreatic, colon, kidney or breast cancer.[3] 
Lapatinib (LAP, see Scheme 1) is a synthetic, orally-active 
quinazoline with antineoplastic properties. It is the first dual 
inhibitor of EGFR and HER2 and was approved by the FDA in 
2007.[4] The mechanism of LAP action involves binding to the 
adenosine triphosphate site, increasing apoptosis and reducing 
cellular proliferation.[5] It is also known that LAP binds strongly to 
albumin (>99%) and undergoes extensive metabolism in humans 
to give numerous oxidized, as well as N- and O-dealkylated 
products (N-LAP and O-LAP, respectively, Scheme 1). Indeed, it 
is known that O-LAP remains active against EGFR but not against 
HER2.[4a] 
The binding of drugs to transport proteins has been widely 
investigated, due to its importance in the pharmacological action 
of the drug in the organism. Thus, processes such as drug 
solubility, toxicity and in vivo half-life are modulated through 
drug@protein complexation.[6] Besides, interaction of these 
complexes with light may result in photosensitivity disorders. For 
this reason, an extensive research effort has been devoted to 
understand the photosensitizing side effects mediated by the 
interaction of biomolecule-bound drugs with light.[7] In fact, drugs 
containing the quinazoline moiety are known to elicit skin 
diseases such as photodermatitis.[8] 
Spectroscopic techniques, such as fluorescence and transient 
absorption, are very useful to investigate drug/protein interactions 
as they allow full characterization of the excited states involved in 
photosensitization. Thus, fluorescence is a highly sensitive 
technique, widely used in the steady-state and time-resolved 
modes to study the structural and dynamic features of 
drug@protein complexation. Likewise, ultrafast transient 
absorption spectroscopy is a powerful tool that can provide key 
information on the excited state dynamics at very short times, as 
they are known to be very sensitive to the microenvironment. 
Accordingly, the very fast photo-initiated processes such as 
intersystem crossing as well as energy or charge-transfer can 
significantly vary depending on the surroundings of the 
investigated chromophore.[7e]  
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Previous reports on the interaction of LAP with human serum 
albumin (HSA) have evidenced static quenching of the intrinsic 
protein emission, allowing the calculation of a binding constant of 
ca. 104 M-1. Based on preliminary theoretical calculations in 
combination with fluorescence experiments using selective site 
probes it has been proposed that LAP mainly interacts in the so-
called site III (subdomain IB) of HSA.[9] With this background, and 
with the aim to obtain a deeper insight into LAP@HSA binding, 
steady-state and time-resolved fluorescence as well as ultrafast 
transient absorption studies, in addition to detailed computational 
analysis on the chromophore including multiconfigurational 
quantum-chemistry calculations (complete-active-space self-
consistent field/complete-active-space second-order perturbation 
theory CASSCF/CASPT2), have been undertaken. Moreover, the 
studies have been extended to the main LAP metabolites namely 
N-LAP and O-LAP, as they retain to some extent the 
photosensitivity and/or pharmacological properties of the parent 
drug. 
Scheme 1. Chemical structures of lapatinib (LAP) and its main metabolites N-
LAP and O-LAP. The dashed frame shows the LAP simplified model containing 
the central -conjugated chromophores for CASSCF/CASPT2 computational 
analysis. 
Results and Discussion 
The photophysical properties of LAP were first investigated in 
organic solution. The emission of the drug in MeCN and ethanol 
was very low at room temperature, in agreement with previous 
observations in methanol.[9c] However, the fluorescence was 
dramatically enhanced in a solid ethanol matrix at 77K (see 
Figures S1 and S2 in the Supporting Information). This effect can 
be attributed to the restriction in the degrees of freedom for 
conformational relaxation in the frozen medium, which could 
prevent a possible intramolecular charge-transfer (ICT), similar to 
that previously observed for related drugs.[10] 
The photobehavior of LAP was also investigated in aqueous 
medium and in the presence of human serum albumin (HSA). In 
PBS LAP is known to form aggregates;[9c] this is clearly shown by 
the UV absorption spectra (see Figure S3 in the Supporting 
Information). However, in the presence of HSA at 1:1 molar ratio 
(10 M), the drug was completely solubilized (see Figure S4 in 
the Supporting Information). Hence, steady-state fluorescence 
measurements were performed on isoabsorptive solutions at two 
excitation wavelengths (295 or 340 nm).  
Emission of LAP@HSA at exc = 295 nm, where both the protein 
and the drug absorb light, is shown in Figure 1A. Under these 
conditions, a clear quenching of the intrinsic protein fluorescence 
centered at 340 nm was observed. Interestingly, while the 
emission of LAP in PBS was unstructured and very minor due to 
aggregation, the profile changed dramatically within the protein 
binding sites; here, the fluorescence of the drug was strongly 
enhanced, and the shape of the spectrum was more structured 
and shifted towards shorter wavelengths (from 470 to 425 nm). 
This effect is very similar to that observed between EtOH at 298 
K and 77 K and can be attributed to the solid matrix effect, in 
addition to the blockage of a possible ICT process. Thus, 
incorporation of LAP to HSA not only avoids aggregation favoring 
its solubility, but it likewise enhances its fluorescence due to the 
more constrained microenvironment that may also help to block 
the charge-transfer process. 
Figure 1. (A) Fluorescence spectra of HSA (black), LAP (dashed blue) and 
LAP@HSA at 1:1 molar ratio (solid blue) in PBS under air, using isoabsorptive 
solutions at exc = 295 nm. The simulated emission of LAP@HSA, determined 
as explained elsewhere[11] taking into account the percentage of photons 
absorbed by HSA and LAP at 295 nm, and considering no interaction between 
the two entities, is shown in dotted blue. (B) Emission of LAP (dashed blue), N-
LAP (dashed red), O-LAP (dashed green), LAP@HSA (blue), N-LAP@HSA 
(red) and O-LAP@HSA (green) at 1:1 molar ratio in PBS under air, using 
isoabsorptive solutions at exc = 340 nm. The inset shows a zoom of the lower 
fluorescence spectra. (C) Fluorescence decay traces and (D) anisotropy decays 
for LAP@HSA (blue) and N-LAP@HSA (red) at 1:1 molar ratio upon excitation 
at 340 nm in aerated PBS. 
The emission of LAP within HSA upon excitation at 295 nm may 
not only arise from the direct absorption of light but also from 
energy transfer with the protein as donor due to spectral overlap 
(see Figure S5A in the Supporting Information). This process, 
which is dynamic in nature, is supported by the femtosecond 
transient absorption results (see below).  
Fluorescence experiments at exc = 295 nm were also done with 
the main metabolites N-LAP and O-LAP. As it can be clearly 
observed from Figure S6 in the Supporting Information, 
interaction of both metabolites with HSA was much weaker than 
that of LAP. For N-LAP, a moderate quenching of the protein 
emission attributable to singlet-singlet energy transfer (SSET) 
was detected, while in the case of O-LAP such quenching was 
insignificant. Indeed, the percentages of decrease of the protein 
emission centered at 340 nm upon interaction with LAP, N-LAP 
and O-LAP were determined to be 54%, 37% and 13%, 
respectively. 
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Selective excitation of the protein bound drug (or metabolite) at 
340 nm evidenced the highest fluorescence yield for LAP (Figure 
1B); yet, emission from N-LAP was lower and less structured than 
that of the parent drug, indicating weaker interaction with HSA, 
while emission from O-LAP either in PBS or within the protein was 
nearly undetectable. This can be associated with a lower 
contribution of ICT states for LAP than for both metabolites within 
the protein. In addition, the negligible fluorescence of O-LAP may 
also be related to an alternative deactivation pathway involving 
deprotonation of the phenol moiety in the excited state. Figure 1C 
displays the fluorescence decay traces for LAP or N-LAP within 
HSA, from which a somewhat shorter lifetime was determined for 
the metabolite (<> = 1.2 ns) than for LAP itself (<> = 1.5 ns); 
this is in line with the steady-state results. Besides, anisotropy 
decays (Figure 1D) evidenced a tight interaction of the drug and 
the metabolite with the protein; thus, LAP@HSA and N-
LAP@HSA decay from r0 ca. 0.22 to a constant value close to 0.1 
within 0.53 and 0.46 ns, respectively, confirming a huge restriction 
in the degrees of freedom for conformational relaxation of the drug, 
or to a lesser extent the metabolite, within the protein. 
With the aim of characterizing in more detail the photobehavior of 
LAP in the first steps upon interaction with light, femtosecond 
transient absorption measurements in acetonitrile and in PBS, in 
the presence of HSA at different excitation wavelengths, were 
performed. In the organic solvent, transient absorption spectra 
during the first 5 ps after excitation at 330 nm (Figure 2A) showed 
an instantaneous formation of two bands centered at 550 and 400 
nm that rapidly evolved towards a new absorption band around 
480 nm, through two isosbestic points at ca. 420 and 510 nm; the 
480 nm transient started to decay at longer times (Figure 2B). 
Figure 2. Femtosecond transient absorption measurements for LAP in 
acetonitrile upon excitation at 330 nm: spectra from (A) 0.5 (black) to 5 ps 
(magenta) and (B) from 5 to 150 ps; decay traces at 550 (black) and 480 nm 
(magenta) at two different time windows: 18 ps (C) and 200 ps (D). 
Analysis of the decay traces at 400 and 550 nm showed that both 
transient bands disappear in a parallel way; two components were 
necessary to get a good fitting, with lifetimes of ca. 90 ps and ca. 
1.5 ps. Interestingly, the shorter one matches with that obtained 
in the formation of the trace at 480 nm (see Figure 2C). Thus, the 
band centered at 550 nm is assigned to the singlet-singlet 
absorption of LAP, that rapidly evolves (≈ 1.5 ps) to another state, 
attributed to the abovementioned ICT state, which displays a 
maximum at 480 nm and decays with a lifetime of ca. 90 ps (see 
Figure 2D). A similar behavior was detected for N-LAP, but with 
different kinetics; in this case, the evolution from the locally 
excited singlet state to ICT is accomplished in ca. 1.9 ps, which 
decays in about 70 ps (see Figure S7 in the Supporting 
Information). 
By contrast with the light absorbing species detected in MeCN, 
the scenario observed in the LAP@HSA (or N-LAP@HSA) 
complexes evidenced formation of only one transient species 
assigned to the singlet-singlet absorption band, with maxima ca. 
420 and 530 nm. For LAP@HSA, its decay followed a second 
order law with two components with lifetimes of ca. 12 ps and 
almost 1 ns (see Figure 3), while for N-LAP@HSA the shorter 
component was found to be of about 8.5 ps, while the longer one 
lasted again up to the ns scale (see Figure S8 in the Supporting 
Information). It is worth to note that ICT formation was blocked 
within the protein cavities, which provide a constrained 
microenvironment less polar and more lipophilic than the bulk 
aqueous medium. 
Figure 3. (A) Femtosecond transient absorption spectra from 1 to 200 ps, and 
(B) decay trace monitored at 530 nm for LAP@HSA at 1:1 molar ratio (3×10-4 
M) in PBS, using 330 nm as excitation wavelength. 
Having discussed the ultrafast dynamics after excitation of the 
LAP@HSA complexes at 330 nm, where LAP is the only light 
absorbing species, it is interesting to come back to the point 
mentioned above regarding the emission from the complexes 
upon excitation at  < 300 nm, when both protein and drug absorb 
light. Under these conditions, LAP fluorescence can result from 
both direct absorption of light by the drug and SSET process from 
HSA to LAP. As a matter of fact, ultrafast transient absorption 
measurements for LAP@HSA upon 280 nm laser excitation (see 
Figure S5B in the Supporting Information) evidenced 
instantaneous formation of the band with maximum centered at 
ca. 530 nm, assigned to 1LAP*, together with a delayed (650 fs) 
growth that occurred up to ca. 900 fs; the latter was assigned to 
the formation of 1LAP* through SSET from the excited Trp residue 
of the protein.  
In order to further characterize the excited states generated after 
light absorption by the drug (or its metabolites), a computational 
analysis was performed on the central -conjugated system 
containing the furan and quinazoline chromophores present in 
LAP, N-LAP and O-LAP (see Scheme 1, dotted frame). The 
secondary amine of LAP breaks the conjugation, so the excitation 
process is mainly driven by the furan and quinazoline rings. Such 
reduction of the molecular size allowed us to carry out a high-level 
CASSCF/CASPT2[12] analysis of the electronic structure 
properties for the ground and excited states, which is required for 
a proper description of localized and charge-transfer states.  
 








































growth 1.5 ps decay 90 ps
 




















decay 1 = 12 ps
2 = 1.1 ns




Figure 4. Main electronic excitations characterizing the photophysics of LAP 
simplified model at the coplanar (A) and twisted (B) structures. 
Based on the herein reported experimental findings pointing to 
two relevant excited states and the possible involvement of an ICT 
with large structural changes, the electronic ground and excited 
states were characterized at two structures A and B (Figure 4) 
with a coplanar orientation of the furan and quinazoline rings and 
with 90⁰-twisted geometry, respectively. Tables S1 and S2 in the 
Supporting Information compile the electronic transition data for 
both structures. At the coplanar arrangement, all the low-lying 
excited states correspond to excitations localized in the 
quinazoline part, the S4 state displaying the brightest electronic 
transition, with a vertical energy of 4.73 eV (Figure 4A). None of 
the computed states have a significant charge-transfer character 
as indicated by the values of the dipole moments and the orbital 
excitations related to each state (see Figure S9 in the Supporting 
Information). In fact, no charge-transfer state was predicted even 
when computing 20 excited states. Such scenario changes upon 
twisting the furan and quinazoline parts (see Figure S10 in the 
Supporting Information). As can be seen in Table S2 in the 
Supporting Information, a new relevant state appears at 5.30 eV 
(S7 state) with a much higher dipole moment () than that of the 
ground state (S0), which corresponds to a charge-transfer 
excitation from the furan ring to the quinazoline moiety (Figure 4B).  
Based on the obtained data and the previous analyses, the 
photophysical properties of LAP at short times after absorbing 
light should be governed by the excited state localized in the 
quinazoline part with a coplanar orientation with the furan ring (as 
in the ground state equilibrium geometry). This state evolves 
towards the charge-transfer state via a twisting of the middle 
single bond which is associated with the growing transient 
absorption signal appearing in the experimental spectra. The 
charge-transfer state must therefore govern the photophysics at 
longer times. 
Further insights into the relative arrangement of the furan and 
quinazoline rings in LAP and its metabolites when binding to HSA, 
along with the interactions responsible for that arrangement, were 
obtained by Molecular Dynamics (MD) simulation studies. The 
binding mode of the ligands to subdomain IB was initially explored 
by Molecular Docking using the program GOLD 5.7.0[13] and the 
protein coordinates found in the crystal structure of HSA in 
complex with hemin (PDB entry 1O9X),[14] which binds to 
subdomain IB. The resulting ligand@HSA binary complexes were 
submerged in a truncated octahedron of water molecules and 
further analyzed by MD simulations using the molecular 
mechanics force field AMBER.[15] This type of studies in which 
both the ligand and the protein are flexible: (i) allows discarding 
false binding modes; and (ii) gives a more realistic conformation 
of the ligand and the ligand@protein complex (induced-fit model). 
The two possible protonation states of the secondary and primary 
amino groups in the ligands were initially considered. However, 
the neutral forms of the ligands were ruled out based on the higher 
stability of their protonated forms in the pocket during the 
simulations. 
The results of these MD simulation studies revealed that the 
proposed binding for LAP and its metabolites in subdomain IB 
obtained by docking was feasible as the complexes proved to be 
stable during the simulation. The root-mean-square deviation 
(rmsd) for the whole protein backbone (C, C, N and O atoms) 
calculated in the three complexes revealed to be low (see Figure 
S11 in the Supporting Information). For the LAP@HSA complex, 
the results showed that: (i) only one conformation among those 
existing in solution for LAP is selected when bound to subdomain 
IB of HSA; and (ii) this conformation is frozen by the protein. Thus, 
selective inversion NOE experiments with LAP in deuterated 
methanol showed a 1:1.9 ratio of the two possible rotamers 
around the furan-quinazoline bond, being the major conformer the 
one in which the oxygen atom of the furan ring is located on the 
same side as the amino group in the quinazoline ring (see Figure 
S12 in the Supporting Information). As shown in Figures 5A and 
5B, the major conformation obtained in solution is selected by 
HSA. More importantly, an almost coplanar arrangement of the 
furan and quinazoline rings was observed during the whole 
simulation. Thus, the analysis of the dihedral angle between the 
furyl (oxygen and C2´ atoms) and quinazoline (C5´ and C4´ 
atoms) moieties in LAP in the LAP@HSA binary complex during 
the simulation revealed that this coplanar arrangement is frozen 
by the protein as no significant changes were identified (Figure 
5E). The average value of the dihedral angle is 7.85º for the last 
80 ns of simulation. In view of the CASSCF/CASPT2 results, this 
arrangement would clearly favor emission from its locally excited 
singlet state, blocking the ICT process; this is in line with the 
experimental results shown above.  
Thus, LAP would be anchored in subdomain IB by two strong 
hydrogen bonding interactions, one between the sulfone oxygen 
atom and the main NH group of Glu119, and another one between 
the main carbonyl group of Val116 and the amino group of the 
ligand, which is mediated by a water molecule (Figure 5B). These 
interactions were observed during 63% and 78% of the simulation, 
respectively. In addition, LAP would be stabilized in subdomain IB 
by numerous favorable non-polar interactions between the 
aromatic part of the ligand and the side chain residues within the 
pocket, specifically Met123, Phe134, Tyr138, Leu139, His146, 
Leu154, Phe157, Tyr161 and Phe165.  
On the contrary, the binding mode of N-LAP in subdomain IB of 
HSA proved to be markedly different from LAP, evidencing a 
reverse binding of the main aromatic rings and, more importantly, 
with much less coplanarity between them (Figures 5C and 5D). 
The analysis of the variation of the aforementioned dihedral angle 
in N-LAP in the N-LAP@HSA binary complex during the whole 
simulation revealed a large rotation around the furan-quinazoline 
bond, with an average value of -59.5º for the last 80 ns of 
simulation (Figure 5F). This non-planar arrangement agrees with 
its lower emission within the protein. Moreover, the N-LAP 
different binding arrangement, its lower conformational restriction 
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Figure 5. Binding mode of LAP (A-B) and N-LAP (C-D) with HSA protein obtained by MD simulation studies. (A,C) Overall views of the LAP@HSA (A) and N-
LAP@HSA (C) binary complexes obtained by MD simulation studies. Snapshots after 60 ns are shown. The main backbone of LAP and N-LAP are shown as yellow 
and violet spheres, respectively. Relevant interactions of LAP (B) and N-LAP (D) with the subdomain IB of HSA. Note how the binding mode of LAP is markedly 
different from N-LAP. Hydrogen bonding interactions between the ligands and the protein are shown as red dashed lines. Relevant side chain residues are shown 
and labelled. (E-F) Variation of the dihedral angle between the furyl and quinazoline moieties of LAP (E) and N-LAP (F) in the LAP@HSA and the N-LAP@HSA 
protein complexes, respectively, during 100 ns of simulation. The bonds involved in the dihedral angle are highlighted with a yellow shadow.
achieved within the protein, as well as its smaller size might 
explain the enhancement of the fluorescence experimentally 
observed after addition of IBP or WRF, while they do not affect 
LAP emission. Thus, IBP and WRF might cause conformational 
changes in the neighboring subdomains that might contribute to 
push N-LAP to a more constrained environment.  
In order to obtain experimental confirmation on the binding site of 
LAP or N-LAP inside the protein, selective site I or site II probes, 
such as warfarin (WRF)[16] or ibuprofen (IBP),[17] were used. 
Addition of either WRF or IBP to LAP@HSA resulted in no 
significant change in the emission of the drug within the protein. 
By contrast, for N-LAP@HSA both probes provoked an 
enhancement of the metabolite emission (see Figure S13 in the 
Supporting Information). Thus, it can be concluded that neither 
LAP nor N-LAP bind preferentially to site I or site II of HSA but to 
a different one. Interestingly, in the case of N-LAP, addition of the 
probes seems to generate greater constraint in the binding site, 
resulting in higher emission. This allosteric effect was previously 
observed with other drugs and site probes interacting with 
proteins, and it is mainly due to large conformational changes in 
the macromolecule upon ligand binding.[18] 
Finally, the MD simulation studies carried out with the nearly non-
emissive O-LAP@HSA binary complex revealed a similar binding 
mode to that of LAP (see Figure S14 in the Supporting 
Information). More importantly, the phenol group of the ligand 
would have the appropriate arrangement to be deprotonated by 
Glu425 (subdomain IIIA), acting as a general base. This 
deprotonation process would be mediated by a water molecule 
network and Lys190, which might explain the rapid deactivation. 
Conclusion 
The photophysical properties of LAP and their main metabolites, 
N-LAP and O-LAP, have been fully characterized in solution and 
in the presence of HSA by means of ultrafast spectroscopy, 
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multiconfigurational quantum-chemistry calculations and MD 
simulation studies. CASSCF/CASPT2 analysis reveals that the 
photobehavior of LAP upon interaction with light is initially 
governed by emissive excited states localized on the quinazoline 
and furan rings in a coplanar orientation, which evolve to twisted 
ICT states. This process has been experimentally confirmed by 
femtosecond transient absorption measurements; thus, a band 
centered at 550 nm is instantaneously formed upon excitation of 
LAP in MeCN, that progresses in about 1.5 ps to an ICT state 
(max ≈ 480 nm). Switching from locally excited to charge-transfer 
emitting states is also supported by steady-state fluorescence 
measurements in ethanol both in solution at room temperature 
and in a solid matrix. Thus, LAP does not display significant 
emission at 298 K, while a strong enhancement is observed at 77 
K probably due to the blockage of ICT in the matrix. A similar 
behavior is evidenced in the protein-bound fluorophore, since the 
weak shapeless and red-shifted emission of LAP (or N-LAP) 
arising from aggregates in PBS is strongly enhanced and much 
more structured within the protein. This is due to a favored 
coplanar orientation between the furan and quinazoline moieties 
within the binding pockets, which is much higher for LAP than for 
N-LAP. Interestingly, MD simulation studies clearly explain this 
effect, showing that the detected emission increases with the 
decreasing dihedral angle between the quinazoline and furan 
rings. Finally, in addition to displacement experiments, simulation 
studies undoubtedly confirm subdomain IB of HSA as the high 
affinity binding site not only for LAP but also for its metabolites N-
LAP and O-LAP. 
Experimental Section 
Chemicals and Reagents 
Lapatinib (CAS 231277-92-2), ibuprofen, warfarin, and human serum 
albumin were purchased from Sigma-Aldrich (Madrid, Spain). N-De[2-
(methylsulfonyl)ethyl lapatinib (N-LAP, CAS 697299-82-4) and O-De(3-
fluorobenzyl) lapatinib ditosylate salt (O-LAP; CAS 1268997-70-1) were 
provided by Santa Cruz Biotechnology (Dallas, USA) and Toronto 
Research Chemicals (North York, Canada), respectively. PBS buffer was 
prepared by dissolving phosphate-buffered saline tablets (Sigma-Aldrich) 
using ultrapure water from a Millipore (Milli-Q Synthesis) system. 
Spectrophotometric HPLC solvents were obtained from Scharlab and used 
without further purification. 
Spectroscopic Measurements 
Steady-state absorption spectra were recorded in a JASCO V-760 
spectrophotometer. Steady-state fluorescence spectra were obtained 
using a JASCO-8500 spectrofluorometer system provided with a 
monochromator in the wavelength range 200-900 nm, with an excitation 
wavelength of 295 or 340 nm at 25 ºC. Measurements on drug or 
metabolite@protein complexes were performed in aerated PBS of 1:1 
molar ratio mixtures at 10 M. 
Time-resolved fluorescence measurements were done using an EasyLife 
X system containing a sample compartment composed of an automated 
peltier cuvette holder to control the temperature, a pulsed LED excitation 
source and a lifetime detector. The employed LED excitation source was 
340 nm, with emission filter of GG400. Anisotropy decays were measured 
by controlling the polarization of the exciting beam with the corresponding 
polarizers. From the parallel and perpendicular measurements, the 
fluorescence anisotropy decay was calculated using the formula: 
𝑟(𝑡) =
𝐼𝑝𝑎𝑟(𝑡) − 𝑅𝐼𝑝𝑒𝑟𝑝(𝑡)
𝐼𝑝𝑎𝑟(𝑡) +  2𝑅𝐼𝑝𝑒𝑟𝑝(𝑡)
 
The transmission under parallel and perpendicular conditions was found 
to be identical so the correction factor R was put to unity. 
The UV and fluorescence measurements were recorded using 10 × 10 
mm2 or 10 × 4 mm2 quartz cells at 25 ºC. The absorbance of the samples 
at the excitation wavelength was kept below 0.1. Fluorescence 
measurements in the solid matrix of ethanol were achieved by introducing 
the solution in a quartz tube of 5 mm of diameter and cooled with liquid N2 
(77 K). 
Femtosecond transient absorption experiments were performed using a 
typical pump-probe system. The femtosecond pulses were generated with 
a mode-locked Ti-Sapphire laser of a compact Libra HE (4 W power at 4 
kHz) regenerative amplifier delivering 100 fs pulses at 800 nm (1 mJ/pulse). 
The output of the laser was split into two parts to generate the pump and 
the probe beams. Thus, tunable femtosecond pump pulses were obtained 
by directing the 800 nm light into an optical parametric amplifier. In the 
present case, the pump was set at 330 nm and passed through a chopper 
prior to focus onto a rotating cell (1 mm optical path) containing the 
samples in organic or aqueous solution. The white light used as probe was 
produced after part of the 800 nm light from the amplifier travelled through 
a computer controlled 8 ns variable optical delay line and impinge on a 
CaF2 rotating crystal. This white light was in turn split in two identical 
portions to generate reference and probe beams that then are focused on 
the rotating cell containing the sample. The pump and the probe were 
made to coincide to interrogate the sample. A computer-controlled imaging 
spectrometer was placed after this path to measure the probe and the 
reference pulses to obtain the transient absorption decays/spectra. The 
experimental data were treated and compensated by the chirp using the 
ExciPro program. 
Computational CASSCF/CASPT2 analysis 
Ground state geometry optimization. The structure of the lapatinib 
simplified model (see Scheme 1) was optimized by means of the density 
functional (DFT) method with the B3LYP functional and the 6-31G* basis 
set as implemented in the GAUSSIAN 09 software package,[19] giving rise 
to the so-called coplanar structure. From the obtained geometry, the 
dihedral angle between the furan and quinazoline moieties was increased 
until 90⁰ resulting in the so-called twisted structure. No significant 
differences for the geometrical parameters have been found by further 
optimizing the geometry with the M06-2X functional and the 6-311G* basis 
set (see Figure S15 in the Supporting Information). 
Electronic transitions. The complete-active-space second-order 
perturbation theory (CASPT2) method[12] and the atomic natural orbital 
(ANO) S-type basis set with a contraction scheme C, N, 
O[3s,2p,1d]/H[2s1p], hereafter ANO-S-VDZP, were used as implemented 
in the MOLCAS 8 program[20] to determine the electronic structure 
properties of the ground and lowest-lying excited states at the coplanar 
and twisted geometries. Ten roots were averaged in the CASSCF 
computations [hereafter, SA(10)-CASSCF]. The most relevant , * and 
nitrogen lone pair (nN) orbitals were selected for the active space, which 
corresponds to a total of 14 active electrons distributed in 12 active orbitals. 
The dynamic electron correlation was computed using the CASPT2 
method using the SA-CASSCF(14,12) wave functions. The ionization-
potential electron-affinity parameter (IPEA) was set to the standard value 
of 0.00 au, which has been successful in many studies in similar molecular 
system with basis sets of the same quality.[21] An imaginary level shift of 
0.2 au was used to minimize the presence of weakly intruder states.[22] 
Oscillator strengths (f) were calculated according to the formula 𝑓 =
(2/3)𝐸 𝑇𝐷𝑀2, where E stands for the CASPT2 vertical absorption energy, 
and TDM refers to the transition dipole moment between the initial φ1 and 
final φ2 SA-CASSCF wave functions, according to the formula 𝑇𝐷𝑀 =
⟨𝜑1|?⃗?|𝜑2⟩, where ?⃗? is the dipole moment operator. 




Molecular Docking  
These calculations have been performed using GOLD 5.7.0 program[13] 
and the protein coordinates were taken from the crystal structure of HSA 
in complex with hemin (PDB entry 1O9X).[14] The experimental procedure 
was similar to that described for 2-acetoxy-4-trifluoromethylbenzoic acid 
(triflusal),[7b] with the exception that the position of hemin was used to 
define the binding pocket, and the radius was set to 10 Å. The protonated 
forms of the ligands (secondary and primary amines) were employed.  
Molecular Dynamics Simulation Studies 
The highest score solution obtained by docking was subjected to 100 ns 
of dynamic simulation. The experimental protocol involved: (i) the 
minimization of the ligands (LAP, N-LAP and O-LAP); (ii) the generation 
and minimization of the binary LAP@HSA, N-LAP@HSA, and O-
LAP@HSA protein complexes using the poses obtained by docking; and 
(iii) MD simulations of the resulting minimized ligand@HSA complexes. 
The protocol was performed as described for triflusal.[7b] The analysis of 
the trajectories and the rmsd of the atomic positions of the protein and the 
ligands during the simulation were analyzed by using the cpptraj module 
in AMBER 16.[15] The protein figures disclosed were created by using the 
molecular graphics program PyMOL.[23] 
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The photophysical properties of the anticancer drug lapatinib and two of its metabolites have been fully characterized in solution and 
in the presence of HSA by means of ultrafast spectroscopy and computational studies; all results point that the geometrical arrangement 
controls their photobehavior. Thus, in a coplanar orientation locally excited states are formed, while in a twisted positioning 
intramolecular charge-transfer states prevails. 
 
ICT





LE (abs=520 nm, ≈1 ns)
(em=425 nm, ≈1 ns)
LE
(abs=550 nm, 1.5 ps)
HSA
